Neusoft and ZENRIN Join Hands to Continuously Empower Chinese Auto Brands in Their Global Expansion

Neusoft and ZENRIN Join Hands to Continuously Empower Chinese Auto Brands in Their Global Expansion

TOKYO, Jan. 24, 2025 /PRNewswire/ -- Recently, Neusoft Corporation (Neusoft, SSE:600718) signed a memorandum of understanding (MOU) with ZENRIN CO., LTD. during the Automotive World 2025 exhibition held in Tokyo, Japan. Both parties announced that...

E-POWER leads global market innovation with LED power supplies

E-POWER leads global market innovation with LED power supplies

SEOUL, South Korea, Jan. 23, 2025 /PRNewswire/ -- E-POWER CO.,LTD, a company specializing in the design and production of LED power supplies, is attracting attention in the global market for its ultra-slim, high-efficiency products. E-POWER produces...

NEXTBIOMEDICAL Receives IDE Approval from FDA for Nexsphere-F™, an Embolic Microsphere for Use in Genicular Artery Embolization (GAE) for Knee Osteoarthritis: The U.S. RESORB Trial Launches

NEXTBIOMEDICAL Receives IDE Approval from FDA for Nexsphere-F™, an Embolic Microsphere for Use in Genicular Artery Embolization (GAE) for Knee Osteoarthritis: The U.S. RESORB Trial Launches

SEOUL, South Korea, Jan. 15, 2025 /PRNewswire/ -- NEXTBIOMEDICAL CO., LTD, a KOSDAQ-listed innovative medical device company in South Korea, proudly announced that it has received Investigational Device Exemption (IDE) approval from the U.S. Food...

MAX to Exhibit at World of Concrete 2025: Introducing Autonomous Mobile Tying Robot, Rebar Tying Unit for Automation

MAX to Exhibit at World of Concrete 2025: Introducing Autonomous Mobile Tying Robot, Rebar Tying Unit for Automation

- Exhibiting Automated Equipment That Aims to Solve Issues in Construction Industry, Including Labor Shortage - TOKYO, Jan. 15, 2025 /PRNewswire/ -- MAX CO., LTD. (hereinafter "MAX," based in Japan), the world's first company to release a...

Alebund Pharmaceutical announced the 1st closing of RMB 550 million in Series C financing

Alebund Pharmaceutical announced the 1st closing of RMB 550 million in Series C financing

SHANGHAI and YANGZHOU, China, Jan. 7, 2025 /PRNewswire/ -- Alebund Pharmaceuticals ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for renal diseases and related chronic conditions,...

menu
menu